CN107028930B - A kind of antiprostate cancer composition and application thereof - Google Patents
A kind of antiprostate cancer composition and application thereof Download PDFInfo
- Publication number
- CN107028930B CN107028930B CN201710298783.XA CN201710298783A CN107028930B CN 107028930 B CN107028930 B CN 107028930B CN 201710298783 A CN201710298783 A CN 201710298783A CN 107028930 B CN107028930 B CN 107028930B
- Authority
- CN
- China
- Prior art keywords
- inonotus obliquus
- prostate cancer
- polysaccharide
- group
- edible fungus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of medical composition and its uses for anti-prostate cancer, described pharmaceutical composition includes inonotus obliquus and optional edible fungus polysaccharide, and the edible fungus polysaccharide is selected from: one of lentinan, pachymaran, ganoderma lucidum polysaccharide or flammulina velutipes are a variety of.The proliferation and migration of prostate gland cancer cell can be effectively suppressed in pharmaceutical composition of the present invention, the immunity of patient itself can not only be enhanced after addition edible fungus polysaccharide, reduce side effect brought by patients with prostate cancer chemotherapy, the activity that inonotus obliquus anti-prostate cancer can also be further enhanced shows the effect of collaboration anti-prostate cancer.
Description
Technical field
The invention belongs to drug fields, and in particular, to a kind of medical composition and its use of anti-prostate cancer.
Background technique
Prostate cancer is the epithelial malignancy for betiding prostate, mostly occurs in 45 years old or more the middle-aged and the old, is complete
The second largest male malignancy of ball, the disease incidence of China's prostate cancer steeply rises in recent years, and it is strong to become China's middle-aging male
The significant threat of health.
Inonotus obliquus, also known as Polyporus picipes, inonotus obliquus are a kind of domestomycetes for being grown in frigid zone, are mainly distributed in China
In the big Xiaoxinanlin Mountains and Changbaishan area, the civil tradition for generally thering is edible Inonotus obliquus to prevent and treat a variety of diseases.Modern study table
Bright Inonotus obliquus includes tens kinds of chemical components, mainly includes steroid compound, aromatic compound, aliphatic compound
Object, triterpene compound, lignan derivatives, alkaloid etc..Modern pharmacology research shows that Inonotus obliquus has a variety of pharmacology
Activity specifically includes: (1) anti-tumor activity, and having document report Inonotus obliquus has anti-liver cancer and anti-, gastric cancer, lung cancer, cervical carcinoma
Activity；(2) antiviral activity has the alcohol composite extract of document report Inonotus obliquus to have the work of anti HIV-1 virus, influenza virus
Property；(3) diabetes are treated, the water extract of Inonotus obliquus has hypoglycemic activity；(4) blood pressure lowering, Adjust-blood lipid；(5) enhancing is exempted from
Epidemic disease power；(6) anti-oxidant；(7) anti-aging etc..
The present invention further screens its anti-tumor active ingredient, therefrom sieves on the Research foundation of existing Inonotus obliquus
Choosing has obtained the monomeric compound that a kind of pair of prostate cancer has excellent inhibitory effect, and passes through its compounding with other compounds
Research, thus obtain it is a kind of can effective anti-prostate cancer pharmaceutical composition.
Summary of the invention
It is an object of the present invention to provide a kind of pharmaceutical composition of anti-prostate cancer, described pharmaceutical composition includes birch
Obliquus and pharmaceutically acceptable carrier.
Preferred described pharmaceutical composition is using inonotus obliquus as sole active agent.
Further, described pharmaceutical composition further includes edible fungus polysaccharide, it is preferred that the edible fungus polysaccharide choosing
From: lentinan (being purchased from Xi'an Bai Chuan biotechnology Co., Ltd), pachymaran (have purchased from Xi'an Bai Chuan biotechnology
Limit responsible company), ganoderma lucidum polysaccharide (be purchased from Xi'an Bai Chuan biotechnology Co., Ltd) or flammulina velutipes (be purchased from Fu Jianhui
Damp Biotechnology Co., Ltd) one of or it is a variety of.
The weight ratio of inonotus obliquus and edible fungus polysaccharide in pharmaceutical composition of the present invention are as follows: 1-3:5-10,
Preferably: 1-2:6-8, more having choosing is 1:8.
The pharmaceutical composition of anti-prostate cancer of the present invention can be prepared into combination of oral medication according to conventional method in that art,
The combination of oral medication is selected from capsule, tablet or granule, wherein the pharmaceutically acceptable carrier is selected from: filling
One of agent, adhesive, disintegrating agent or lubricant are a variety of, it is preferred that the filler be selected from starch, dextrin, lactose or
Microcrystalline cellulose, described adhesive are selected from: cellulose derivative, pregelatinized starch, povidone, and the disintegrating agent is selected from: carboxylic first
Base sodium starch, croscarmellose sodium, crospovidone, the lubricant are selected from: talcum powder, magnesium stearate or micro mist silicon
Glue, it is preferred that the cellulose derivative is selected from: methylcellulose, hydroxypropyl cellulose, sodium carboxymethylcellulose or ethyl are fine
Dimension element.
It is a further object to provide inonotus obliquus to prepare the purposes in antiprostate cancer.
It is also another object of the present invention to provide the compositions of inonotus obliquus and edible fungus polysaccharide to prepare anti-forefront
Purposes in gland cancer drug, it is preferred that the edible fungus polysaccharide is selected from: lentinan, pachymaran, ganoderma lucidum polysaccharide or acupuncture needle
One of mushroom polysaccharide is a variety of.
Beneficial effect
The present invention screens in the ingredient of Inonotus obliquus complexity obtains obviously inhibiting prostate gland cancer cell to be proliferated and migrate
Monomeric compound inonotus obliquus pass through to obtain a kind of pharmaceutical composition with clear anti-prostate cancer effect
After showing inonotus obliquus by compounding with edible fungus polysaccharide with the composition research of other compounds, food can be not only played
The intrinsic effect of the side effect brought by fungi polysaccharide enhancing immunity of organisms, reduction chemotherapy, it is brown can also to significantly increase birch
The anti-prostate cancer activity of hole rhzomorph, shows apparent synergistic function, thus before further providing a kind of resist
Column gland cancer effect more preferably pharmaceutical composition.
Specific embodiment
The present invention is described below in more detail to facilitate the understanding of the present invention.
It should be understood that the term or word used in the specification and in the claims is not construed as having
The meaning limited in dictionary, and be interpreted as having on the basis of following principle and its meaning one in the context of the present invention
The meaning of cause: the concept of term can suitably limit best illustration of the invention by inventor.
A kind of embodiment 1: tablet of anti-prostate cancer
The tablet of the anti-prostate cancer is prepared according to the following steps:
(1) it is crushed respectively after weighing each ingredient by recipe quantity, crosses 80 meshes；
(2) inonotus obliquus of recipe quantity, lentinan, ganoderma lucidum polysaccharide, microcrystalline cellulose, pregelatinized starch are put into height
Fast wet granulator is added suitable quantity of water granulation, crosses 20 mesh sieves after dry, add the crospovidone and stearic acid of recipe quantity
Magnesium, after mixing tabletting up to anti-prostate cancer of the present invention tablet.
A kind of embodiment 2: capsule of anti-prostate cancer
The anti-prostate cancer capsule, prepares in accordance with the following steps:
(1) it crushes, sieves with 100 mesh sieve respectively after weighing each ingredient by recipe quantity；
(2) inonotus obliquus of recipe quantity, lentinan, ganoderma lucidum polysaccharide, microcrystalline cellulose, pregelatinized starch are put into height
Fast wet granulator is added suitable quantity of water granulation, crosses 20 mesh sieves after dry；
(3) step (2) particle in add recipe quantity magnesium stearate after be uniformly mixed；
(4) by obtained by step (3) it is particles filled in gelatine capsule shell up to anti-prostate cancer capsule of the present invention.
Effect example 1: the influence to prostate gland cancer cell proliferation
1.1 experimental drug
(1) blank group: 1640 culture medium of serum-free；
(2) inonotus obliquus group: addition 1640 culture medium of serum-free is configured to the suspension that content is 5%；
(3) it polysaccharide group: is trained according to the proportional arrangement of 1:1 at 20% serum-free 1640 according to ganoderma lucidum polysaccharide, lentinan
Support based sols；
(4) Inonotus obliquus extract group: weighing Inonotus obliquus extract, and 1640 culture medium of serum-free for being configured to 5% mixes
Suspension；
(5) complex group: weighing inonotus obliquus, ganoderma lucidum polysaccharide and lentinan, be configured to containing 2% inonotus obliquus,
The compound suspension of 1640 culture medium of serum-free of 20% polysaccharide.
1.2 experimental method
The Human Prostate Cancer Cells (PC-3) of logarithmic growth phase, with 5 × 103The density in/hole is inoculated in 96 orifice plates, every hole
200 μ L, addition are put into 37 DEG C containing 5%CO after 1640 culture mediums containing 10% fetal calf serum2Incubator in cultivate 24 hours.
96 orifice plates set up blank group, inonotus obliquus group, polysaccharide group, Inonotus obliquus extract group, complex group separately, and every group 10
Multiple holes, each group add relative medicine, and wherein blank group adds 1640 culture medium of serum-free, inonotus obliquus group is final concentration of 1%,
Polysaccharide group is final concentration of 10%, Inonotus obliquus extract group is final concentration of 2%, inonotus obliquus is final concentration of in complex group
0.5%, final concentration of the 5% of polysaccharide, continue after cultivating 48h, continues to cultivate 4h, after discarding supernatant, every hole after adding MTT solution
150 μ L of DMSO is added, after 10min fullys shake, measures 570nm absorbance value using microplate reader, calculates each group inhibiting rate, tool
Body result is referring to table 1.
Inhibiting rate (%)=(control group-sample sets) control group × 100%
1 experimental result of table shows complex polysaccharide, inonotus obliquus and the brown hole of birch of ganoderma lucidum polysaccharide and lentinan composition
Fungus extract shows the activity of certain inhibition prostate cancer cell proliferation, and wherein inonotus obliquus inhibits human prostate
Cancer cell multiplication activity highest, hence it is evident that be higher than Inonotus obliquus extract group, before showing that inonotus obliquus has excellent inhibition people
Although the activity of column adenocarcinoma cell proliferation, polysaccharide group also show the proliferation activity of certain inhibition Human Prostate Cancer Cells, but
Although inonotus obliquus dosage is reduced after inonotus obliquus is compounded with polysaccharide group, proliferation of the complex group to Human Prostate Cancer Cells
Inhibitory activity but significantly improves, to show that inonotus obliquus has the activity for cooperateing with anti-prostate cancer with edible fungus polysaccharide.
Table 1, the influence to PC-3 cell Proliferation
Effect example 2: the influence to migration of prostate cancer cells.
2.1 experimental drug
(1) blank group: 1640 culture medium of serum-free；
(2) inonotus obliquus group: addition 1640 culture medium of serum-free is configured to the suspension that content is 5%；
(3) it polysaccharide group: is trained according to the proportional arrangement of 1:1 at 20% serum-free 1640 according to ganoderma lucidum polysaccharide, lentinan
Support based sols；
(4) Inonotus obliquus extract group: weighing Inonotus obliquus extract, and 1640 culture medium of serum-free for being configured to 5% mixes
Suspension；
(5) complex group: weighing inonotus obliquus, ganoderma lucidum polysaccharide and lentinan, be configured to containing 2% inonotus obliquus,
The compound suspension of 1640 culture medium of serum-free of 20% polysaccharide.
2.2 experimental method
24 orifice plates are added in the Human Prostate Cancer Cells (PC-3) of logarithmic growth phase, contain 5%CO in 37 DEG C2Incubator
Middle culture, 1640 culture mediums of the addition containing 10% fetal calf serum are changed to free serum culture when cell fusion 80%-90%
Base continues culture 12 hours, with 100 μ L liquid transfer gun heads along each bore dia scratch of 24 orifice plates, washes cell twice using PBS, discard
After PBS, after 1640 culture mediums of the equivalent containing 10% fetal calf serum are added, scratch area relative distance D1 is recorded under mirror.24 orifice plates point
If blank group, inonotus obliquus group, polysaccharide group, Inonotus obliquus extract group, complex group, every group of 4 multiple holes, each group addition is accordingly
Drug, wherein blank group adds pure water, and inonotus obliquus group is final concentration of 1%, polysaccharide group is final concentration of 10%, Inonotus obliquus
Extract group is final concentration of 2%, inonotus obliquus final concentration of 0.5% in complex group, and final concentration of the 5% of polysaccharide, continue to train
After supporting 48h, scratch area relative distance D2 is measured under mirror, calculates moving distance D3 of the cell to region of causing injury.Calculate each group migration
Inhibiting rate, concrete outcome is referring to table 2.
Inhibition of metastasis rate (%)=(control group-sample sets) control group × 100%
Table 2, the influence to PC-3 cell migration
Note: compared with blank group: P < 0.01 * P < 0.05, * *.
2 experimental result of table shows that individual inonotus obliquus has had the effect of inhibiting Human Prostate Cancer Cells migration,
Although Inonotus obliquus extract group also shows the effect of certain inhibition Human Prostate Cancer Cells migration, but inhibitory effect is not
Obviously, and ganoderma lucidum polysaccharide and lentinan composition complex polysaccharide do not show then inhibit migration of prostate cancer cells effect,
Its final cell migration distance is even also longer than blank group.It is made of with lentinan inonotus obliquus with ganoderma lucidum polysaccharide compound
Group inhibits the effect of Human Prostate Cancer Cells migration the most excellent, hence it is evident that be higher than individual inonotus obliquus group, to show
To not have can be bright after inhibiting the ganoderma lucidum polysaccharide of Human Prostate Cancer Cells migration effect, lentinan to compound with inonotus obliquus group
The Human Prostate Cancer Cells inhibition of metastasis effect of aobvious enhancing inonotus obliquus.
Claims (2)
1. inonotus obliquus is preparing the purposes in antiprostate cancer.
2. the composition of inonotus obliquus and edible fungus polysaccharide is preparing the purposes in antiprostate cancer, described edible true
Granulose is selected from: one of lentinan, pachymaran, ganoderma lucidum polysaccharide or flammulina velutipes are a variety of.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710298783.XA CN107028930B (en) | 2017-04-27 | 2017-04-27 | A kind of antiprostate cancer composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710298783.XA CN107028930B (en) | 2017-04-27 | 2017-04-27 | A kind of antiprostate cancer composition and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107028930A CN107028930A (en) | 2017-08-11 |
| CN107028930B true CN107028930B (en) | 2019-10-29 |
Family
ID=59537992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710298783.XA Expired - Fee Related CN107028930B (en) | 2017-04-27 | 2017-04-27 | A kind of antiprostate cancer composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107028930B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101391958A (en) * | 2008-11-10 | 2009-03-25 | 马宏达 | Extraction method of medicinal fungus inonotus obliquus component |
-
2017
- 2017-04-27 CN CN201710298783.XA patent/CN107028930B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101391958A (en) * | 2008-11-10 | 2009-03-25 | 马宏达 | Extraction method of medicinal fungus inonotus obliquus component |
Non-Patent Citations (2)
| Title |
|---|
| 噻唑蓝法测定香菇多糖体外对癌细胞毒作用;胡静娜;《医药导报》;20130430;第32卷(第4期);464-466 * |
| 灵芝多糖的药理学作用（摘要）;刘立萍;《第七次临床中药学术研讨会论文集》;20141101;126 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107028930A (en) | 2017-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Polysaccharide from Ganoderma atrum evokes antitumor activity via Toll-like receptor 4-mediated NF-κB and mitogen-activated protein kinase signaling pathways | |
| CN105963637B (en) | Application of cryptotanshinone and curcumin in preparation of tumor treatment medicine | |
| CN107714949A (en) | Dendrobium candidum is preparing the application process in treating hypertension drug | |
| CN102000030B (en) | Arbidol dry suspension and preparation method thereof | |
| CN104922181A (en) | Preparation composition containing broccoli extract with effects of improving immunity and suppressing tumors and preparation method of preparation composition | |
| CN101380346A (en) | Traditional Chinese composition for treating tumor and production method thereof | |
| CN101309692A (en) | Application of curbitacin or curbitacin combination in leucocyte increasing medicament preparation | |
| CN102406669B (en) | Chinese medicine composite and preparation method and medicinal preparation thereof | |
| CN107028930B (en) | A kind of antiprostate cancer composition and application thereof | |
| CN1919339B (en) | Cucurbitacin nano preparation comprising protein, preparation method and use thereof | |
| CN101229175A (en) | Medical applications of couple protopanoxadiol derivatives and compound body thereof | |
| CN104069194B (en) | A kind of Chinese medicine composition with antitumaous effect and its production and use | |
| CN105169107A (en) | Anti-depression dispersible traditional Chinese medicine tablet | |
| CN103919850B (en) | A kind of pharmaceutical composition and its application in antineoplastic is prepared | |
| CN107582866B (en) | Application method of dendrobium officinale and amlodipine in preparation of medicine for treating hypertension | |
| CN106389430B (en) | A kind of felodipine Isosorbide Nitrate compound slow-release tablet and preparation method | |
| CN101537013A (en) | Application of nanometer polysaccharide for preparing antineoplastic medicament | |
| CN105833173B (en) | Application of oridonin and curcumin in preparation of medicament for treating leukemia | |
| CN101199534B (en) | Anti-tumor function of raw panoxadiol derivative | |
| CN105687208B (en) | Application of cycloastragenol in preparation of medicine for treating heart failure | |
| CN103655600A (en) | Drug composition for treating cancers, preparation method and applications | |
| TWI462742B (en) | A use of an herbal extract for manufacturing drugs against sarcoma | |
| CN106511360A (en) | Composition containing ginsenoside Rg3 and silymarin and medicine | |
| WO2016049811A1 (en) | Antitumour composition rich in triterpenoids and preparation method thereof | |
| CN104800193A (en) | Pharmaceutical use of guaiol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20191029 Termination date: 20200427 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |